Acasti Pharma (ACST) and Its Competitors Financial Review

Acasti Pharma (NASDAQ: ACST) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Acasti Pharma to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Valuation and Earnings

This table compares Acasti Pharma and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Acasti Pharma $30,000.00 -$16.77 million -1.30
Acasti Pharma Competitors $1.95 billion $126.73 million -8.12

Acasti Pharma’s rivals have higher revenue and earnings than Acasti Pharma. Acasti Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Acasti Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acasti Pharma N/A -345.38% -163.45%
Acasti Pharma Competitors -2,656.27% -68.45% -24.43%

Institutional & Insider Ownership

3.3% of Acasti Pharma shares are owned by institutional investors. Comparatively, 46.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Acasti Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Acasti Pharma’s rivals have a beta of 1.03, suggesting that their average stock price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Acasti Pharma and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acasti Pharma 0 0 2 0 3.00
Acasti Pharma Competitors 3709 10864 24797 812 2.57

Acasti Pharma presently has a consensus target price of $7.00, indicating a potential upside of 607.07%. As a group, “Pharmaceutical preparations” companies have a potential upside of 57.35%. Given Acasti Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Acasti Pharma is more favorable than its rivals.


Acasti Pharma rivals beat Acasti Pharma on 7 of the 12 factors compared.

About Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with's FREE daily email newsletter.

Leave a Reply